IL262986A - Methods of treating behavioral syndromes using pipradrol - Google Patents

Methods of treating behavioral syndromes using pipradrol

Info

Publication number
IL262986A
IL262986A IL262986A IL26298618A IL262986A IL 262986 A IL262986 A IL 262986A IL 262986 A IL262986 A IL 262986A IL 26298618 A IL26298618 A IL 26298618A IL 262986 A IL262986 A IL 262986A
Authority
IL
Israel
Prior art keywords
pipradrol
methods
treating behavioral
behavioral syndromes
syndromes
Prior art date
Application number
IL262986A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of IL262986A publication Critical patent/IL262986A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL262986A 2016-05-26 2018-11-13 Methods of treating behavioral syndromes using pipradrol IL262986A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662341855P 2016-05-26 2016-05-26
PCT/US2017/034443 WO2017205606A1 (en) 2016-05-26 2017-05-25 Methods of treating behavioral syndromes using pipradrol

Publications (1)

Publication Number Publication Date
IL262986A true IL262986A (en) 2018-12-31

Family

ID=60408578

Family Applications (1)

Application Number Title Priority Date Filing Date
IL262986A IL262986A (en) 2016-05-26 2018-11-13 Methods of treating behavioral syndromes using pipradrol

Country Status (10)

Country Link
US (3) US9827233B1 (https=)
EP (1) EP3439657A4 (https=)
JP (1) JP2019517469A (https=)
KR (1) KR20190013737A (https=)
CN (1) CN109414435A (https=)
AU (1) AU2017268795A1 (https=)
CA (1) CA3025473A1 (https=)
IL (1) IL262986A (https=)
MX (1) MX2018013973A (https=)
WO (1) WO2017205606A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
KR20190013737A (ko) * 2016-05-26 2019-02-11 오비드 테라퓨틱스 인크. 피프라드롤을 이용한 행동 증후군들의 치료 방법들
CN111328282A (zh) * 2017-09-12 2020-06-23 奥维德医疗公司 加波沙朵在治疗发作性睡病中的用途
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
US11123332B2 (en) 2018-11-21 2021-09-21 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
EP3880201A4 (en) 2018-12-17 2022-07-27 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF NON-24 HOUR SLEEP waking disorder
GB201911056D0 (en) * 2019-08-02 2019-09-18 Sanchez Hector Mario Treatment of ADD/ADHD
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US5650521A (en) * 1995-12-29 1997-07-22 Guilford Pharmaceuticals Inc. Pyrrolidine derivatives
WO2008095221A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of adhd
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
US8865746B2 (en) 2008-07-18 2014-10-21 Zafgen, Inc. Methods of treating an overweight or obese subject
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20100260844A1 (en) * 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US20120302590A1 (en) * 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
EP2575853B1 (en) 2010-05-25 2016-08-24 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient
DK3272342T3 (da) * 2011-03-23 2021-06-07 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af opmærksomhedsforstyrrelse
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
KR20190013737A (ko) * 2016-05-26 2019-02-11 오비드 테라퓨틱스 인크. 피프라드롤을 이용한 행동 증후군들의 치료 방법들

Also Published As

Publication number Publication date
KR20190013737A (ko) 2019-02-11
WO2017205606A1 (en) 2017-11-30
US20170340619A1 (en) 2017-11-30
CA3025473A1 (en) 2017-11-30
JP2019517469A (ja) 2019-06-24
CN109414435A (zh) 2019-03-01
EP3439657A1 (en) 2019-02-13
EP3439657A4 (en) 2019-12-18
US10493069B2 (en) 2019-12-03
US9827233B1 (en) 2017-11-28
US20190076415A1 (en) 2019-03-14
AU2017268795A1 (en) 2018-11-22
US20180036298A1 (en) 2018-02-08
MX2018013973A (es) 2019-03-28

Similar Documents

Publication Publication Date Title
IL279627A (en) A method for treating depression
IL262986A (en) Methods of treating behavioral syndromes using pipradrol
IL282655A (en) Methods of treating developmental disorders using pipradrol
SG11201706766WA (en) Materials and methods for treatment of hemoglobinopathies
ZA201706059B (en) Method of treatment with tradipitant
GB2553919B (en) Biomass treatment apparatus
GB201410116D0 (en) Method of treatment
ZA201705877B (en) Method of treating diseases
ZA201808607B (en) Methods of treating prader-willi syndrome
GB201706406D0 (en) Method of treatment
EP3684342C0 (en) TREATMENT PROCEDURES
PT3666258T (pt) Método de tratar a síndrome de prader-willi
GB201815588D0 (en) Method of treatment
HUE069644T2 (hu) Eljárás és berendezés sajtolt idomok elõállítására
IL253028B (en) treatment method
IL253847A0 (en) Methods of treating diseases
IL265568A (en) Methods for treating TIM-3 elevation
GB201612445D0 (en) Method and apparatus for vermin treatment
GB201602802D0 (en) Method of treatment
GB2527046B (en) Device and method for the treatment of crops
GB201500555D0 (en) Method and device for the treatment of diseases
GB201512139D0 (en) Methods of treatment
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment
GB201709554D0 (en) Method of treatment